keyword
MENU ▼
Read by QxMD icon Read
search

advanced colorectal cancer

keyword
https://www.readbyqxmd.com/read/28632865/effect-of-first-line-chemotherapy-combined-with-cetuximab-or-bevacizumab-on-overall-survival-in-patients-with-kras-wild-type-advanced-or-metastatic-colorectal-cancer-a-randomized-clinical-trial
#1
Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A Meyerhardt, Deborah Schrag, Claire Greene, Bert H O'Neil, James Norman Atkins, Scott Berry, Blase N Polite, Eileen M O'Reilly, Richard M Goldberg, Howard S Hochster, Richard L Schilsky, Monica M Bertagnolli, Anthony B El-Khoueiry, Peter Watson, Al B Benson, Daniel L Mulkerin, Robert J Mayer, Charles Blanke
Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer...
June 20, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28632850/cetuximab-or-bevacizumab-with-first-line-chemotherapy-in-advanced-kras-wild-type-colorectal-cancer-no-difference-but-not-the-same
#2
Christopher H Lieu, Wells A Messersmith
No abstract text is available yet for this article.
June 20, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28632728/downregulation-of-serum-metabolite-gta-446-as-a-novel-potential-marker-for-early-detection-of-colorectal-cancer
#3
Tsuyoshi Hata, Ichiro Takemasa, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori
BACKGROUND: We previously reported that GTA-446 may be a useful biomarker for early detection of colorectal cancer. In the present study, we confirmed the clinical feasibility of GTA-446 as a screening tool for colorectal cancer with a novel measurement system developed for clinical use. We also improved sensitivity by analysing GTA-446 levels according to gender. METHODS: Serum samples were collected from 225 colorectal cancer patients and 916 healthy volunteers to measure GTA-446 levels by flow injection analysis-mass spectrometry...
June 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28632726/infradiaphragmatic-irradiation-and-high-procarbazine-doses-increase-colorectal-cancer-risk-in-hodgkin-lymphoma-survivors
#4
Anna M van Eggermond, Michael Schaapveld, Cécile Pm Janus, Jan Paul de Boer, Augustinus Dg Krol, Josée M Zijlstra, Richard Wm van der Maazen, Leontien C Kremer, Monique E van Leerdam, Marieke Wj Louwman, Otto Visser, Marie L De Bruin, Berthe Mp Aleman, Flora E van Leeuwen
BACKGROUND: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation fields and chemotherapy regimens. METHODS: In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was compared with general population rates. Treatment effects were quantified by Cox regression analyses...
June 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28632725/the-role-of-primary-tumour-sidedness-egfr-gene-copy-number-and-egfr-promoter-methylation-in-ras-braf-wild-type-colorectal-cancer-patients-receiving-irinotecan-cetuximab
#5
Laura Demurtas, Marco Puzzoni, Riccardo Giampieri, Pina Ziranu, Valeria Pusceddu, Alessandra Mandolesi, Chiara Cremolini, Gianluca Masi, Fabio Gelsomino, Carlotta Antoniotti, Cristian Loretelli, Fausto Meriggi, Alberto Zaniboni, Alfredo Falcone, Stefano Cascinu, Mario Scartozzi
BACKGROUND: The data from randomised trials suggested that primary tumour sidedness could represent a prognostic and predictive factor in colorectal cancer (CRC) patients, particularly during treatment with anti-epidermal growth factor receptor (EGFR) therapy. However, an in-deep molecular selection might overcome the predictive role of primary tumour location in this setting. METHODS: We conducted a retrospective analysis in which tumour samples from RAS/BRAF wild-type (WT) metastatic CRC patients treated with second-third-line irinotecan/cetuximab were analysed for EGFR gene copy number (GCN) and promoter methylation...
June 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28631253/portal-branch-ligation-does-not-counteract-the-inhibiting-effect-of-temsirolimus-on-extrahepatic-colorectal-metastatic-growth
#6
Sebastian Senger, Jens Sperling, Barbara Oberkircher, Martin K Schilling, Otto Kollmar, Michael D Menger, Christian Ziemann
The mTor-inhibitor temsirolimus (TEM) has potent anti-tumor activities on extrahepatic colorectal metastases. Treatment of patients with advanced disease may require portal branch ligation (PBL). While PBL can induce intrahepatic tumor growth, the effect of PBL on extrahepatic metastases under TEM treatment is unknown. Therefore, we analyzed the effects of TEM treatment on extrahepatic metastases during PBL-associated liver regeneration. GFP-transfected CT26.WT colorectal cancer cells were implanted into the dorsal skinfold chamber of BALB/c-mice...
June 19, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28629637/direct-medical-cost-associated-with-colorectal-cancer-in-north-of-jordan
#7
Qais Alefan, Rana Malhees, Nizar Mhaidat
Colorectal cancer (CRC) is mainly characterized as the malignant and impaired growth of rectal cells in the intestinal region. Direct medical cost is related to resources, which are directly used in treating the patient, that mainly includes the cost of drugs, diagnostic, treatment, follow-up, rehabilitation, and hospital admission. The objective of this study is to estimate and analyze direct medical costs attributable to CRC in Jordan. A retrospective analysis of a cohort patients treated for CRC data has been performed to determine direct medical costs attributable to CRC in Jordan...
May 15, 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/28629632/rationale-for-immunological-approaches-to-breast-cancer-therapy
#8
Gwennaëlle C Monnot, Pedro Romero
Despite great advances in early detection, as well as surgical resection of breast tumours, breast cancer remains the deadliest cancer for women worldwide. Moreover, its incidence is without pair, accounting for twice as many new cancer cases as the second most prevalent cancer, colorectal carcinoma. There is therefore a strong need for new therapeutic approaches to breast cancers. Immunotherapies are novel treatment modalities which aim to use immune mediators to attack cancerous cells. Recent clinical results show that these may not only mediate tumour regressions but also cures in some cases...
June 16, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28628975/highly-expressed-long-non-coding-rna-nnt-as1-promotes-cell-proliferation-and-invasion-through-wnt-%C3%AE-catenin-signaling-pathway-in-cervical-cancer
#9
Fangfang Hua, Shanshan Liu, Lihong Zhu, Ning Ma, Shan Jiang, Jun Yang
BACKGROUND: Cervical cancer is the most common gynecological malignancies in women worldwide. The previous study showed that lncRNA NNT-AS1 could play an important role in tumor development and metastasis of colorectal cancer. However, little is known about the function of NNT-AS1 in cervical cancer. The aim of this study was to investigate the expression profile of NNT-AS1 in cervical cancer and assess its possible molecular mechanism. METHODS: Relative expression levels of NNT-AS1 in cervical cancer tissues were determined by qRT-PCR...
June 13, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28628706/diagnostic-accuracy-of-fecal-immunochemical-test-in-patients-at-increased-risk-for-colorectal-cancer-a-meta-analysis
#10
Anastasia Katsoula, Paschalis Paschos, Anna-Bettina Haidich, Apostolos Tsapas, Olga Giouleme
Importance: The potential role of the fecal immunochemical test (FIT) for screening patients at increased risk for colorectal cancer (CRC) has not yet been elucidated. Objective: To assess the diagnostic accuracy of FIT for CRC or advanced neoplasia (AN) in asymptomatic patients at above-average risk. Data Sources: MEDLINE, EMBASE, Cochrane Library, and gray literature sources through August 2016. Study Selection: Diagnostic studies evaluating the accuracy of FIT for CRC or AN in patients with a personal or familial history of CRC using colonoscopy as the reference standard...
June 19, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28628565/open-versus-laparoscopic-surgery-for-advanced-low-rectal-cancer-a-large-multicenter-propensity-score-matched-cohort-study-in-japan
#11
Koya Hida, Ryosuke Okamura, Yoshiharu Sakai, Tsuyoshi Konishi, Tomonori Akagi, Tomohiro Yamaguchi, Takashi Akiyoshi, Meiki Fukuda, Seiichiro Yamamoto, Michio Yamamoto, Tatsuto Nishigori, Kenji Kawada, Suguru Hasegawa, Satoshi Morita, Masahiko Watanabe
BACKGROUND: Laparoscopic surgery for rectal cancer is widely performed all over the world and several randomized controlled trials have been reported. However, the usefulness of laparoscopic surgery compared with open surgery has not been demonstrated sufficiently, especially for the low rectal area. OBJECTIVE: The aim of this study was to investigate the hypothesis that laparoscopic primary tumor resection is safe and effective when compared with the open approach for locally advanced low rectal cancer...
June 16, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28628391/interest-and-attitudes-of-patients-with-advanced-cancer-with-regard-to-secondary-germline-findings-from-tumor-genomic-profiling
#12
Jada G Hamilton, Elyse Shuk, Margaux C Genoff, Vivian M Rodríguez, Jennifer L Hay, Kenneth Offit, Mark E Robson
PURPOSE: Tumor genomic profiling (TGP) can reveal secondary findings about inherited disease risks in a patient with cancer. Little is known about how patients with advanced cancer, currently the primary users of TGP, perceive the benefits and harms of secondary germline findings. METHODS: We conducted semistructured interviews with 40 patients with advanced breast, bladder, colorectal, or lung cancer who had TGP. Qualitative interview data were evaluated by using a thematic content analysis approach...
June 19, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28628120/intestinal-cancer-progression-by-mutant-p53-through-the-acquisition-of-invasiveness-associated-with-complex-glandular-formation
#13
M Nakayama, E Sakai, K Echizen, Y Yamada, H Oshima, T-S Han, R Ohki, S Fujii, A Ochiai, S Robine, D C Voon, T Tanaka, M M Taketo, M Oshima
Tumor suppressor TP53 is frequently mutated in colorectal cancer (CRC), and most mutations are missense type. Although gain-of-functions by mutant p53 have been demonstrated experimentally, the precise mechanism for malignant progression in in vivo tumors remains unsolved. We generated Apc(Δ716) Trp53(LSL•R270H) villin-CreER compound mice, in which mutant p53(R270H) was expressed in the intestinal epithelia upon tamoxifen treatment, and examined the intestinal tumor phenotypes and tumor-derived organoids...
June 19, 2017: Oncogene
https://www.readbyqxmd.com/read/28627973/profile-of-gene-expression-of-tlr-signaling-pathways-in-colorectal-cancer-tissues
#14
Martyna Bednarczyk, Małgorzata Muc-Wierzgoń, Katarzyna Walkiewicz, Teresa Kokot, Edyta Fatyga, Urszula Mazurek
Toll-like receptors (TLRs) are involved in transduction of molecular signals in immune process such as induction and regulation of immunity, production of cytokines, and recognition of specific molecular patterns on the surface of microorganisms, but also in cancer development-which was partially proven in previous studies. There is a lack of detailed research on differentiating levels of TLR expression in colorectal cancer at different stages of its advancement, so in our study we want to determine whether there is such a difference of TLRs and TLR-connected protein expression...
June 1, 2017: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/28625419/recommendation-of-colorectal-cancer-testing-among-primary-care-patients-younger-than-50-with-elevated-risk
#15
Celette Sugg Skinner, Chul Ahn, Ethan A Halm, Wendy Pechero Bishop, Katharine McCallister, Joanne M Sanders, David Farrell, Noel Santini, Amit G Singal
In the era of precision medicine, efforts are needed to identify and tailor screening recommendations among elevated-risk patients. Individuals younger than 50years are an important target population, as they comprise 15% of colorectal (CRC) cases and often present with more advanced disease than their 50+ counterparts. In this large study, 2470 patients ages 25-49 used a tablet-based program that assessed risks, matched risks with screening guidelines, and generated tailored printed guideline-concordant recommendations for patients and their providers...
June 15, 2017: Preventive Medicine
https://www.readbyqxmd.com/read/28624785/trib1-promotes-colorectal-cancer-cell-migration-and-invasion-through-activation-mmp-2-via-fak-src-and-erk-pathways
#16
Yuhui Wang, Nan Wu, Bo Pang, Dandan Tong, Donglin Sun, Haiming Sun, Chunyu Zhang, Wenjing Sun, Xiangning Meng, Jing Bai, Feng Chen, Jingshu Geng, Songbin Fu, Yan Jin
Colorectal cancer (CRC) is the third most common cancer in the world and distant metastasis is the leading cause of death among CRC patients. However, the underlying mechanisms of distant metastasis remain largely unknown. Amplification of 8q24 is a common chromosomal abnormality in CRC. In the present study, a putative oncogene at 8q24, TRIB1, was characterized for its role in CRC metastasis and underlying molecular mechanisms. Higher expression of TRIB1 protein was detected in 58/83 (69.9%) of CRC tissues, compared with adjacent non-tumor tissues...
May 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28622365/association-between-socioeconomic-deprivation-and-colorectal-cancer-screening-outcomes-low-uptake-rates-among-the-most-and-least-deprived-people
#17
Andrea Buron, Josep M Auge, Maria Sala, Marta Román, Antoni Castells, Francesc Macià, Mercè Comas, Carolina Guiriguet, Xavier Bessa, Xavier Castells
BACKGROUND: Screening with faecal occult blood tests reduces colorectal cancer-related mortality; however, age, sex and socioeconomic factors affect screening outcomes and could lead to unequal mortality benefits. The aim of this study was to describe the main outcomes of the population-based Barcelona colorectal cancer screening programme (BCRCSP) by deprivation. METHODS: Retrospective study of the eligible population of the first round of the BCRCSP. Participants' postal addresses were linked with the MEDEA database to obtain the deprivation quintiles (Dq)...
2017: PloS One
https://www.readbyqxmd.com/read/28622298/tgf%C3%AE-pathway-limits-dedifferentiation-following-wnt-and-mapk-pathway-activation-to-suppress-intestinal-tumourigenesis
#18
Patrizia Cammareri, David F Vincent, Michael C Hodder, Rachel A Ridgway, Claudio Murgia, Max Nobis, Andrew D Campbell, Julia Varga, David J Huels, Chithra Subramani, Katie L H Prescott, Colin Nixon, Ann Hedley, Simon T Barry, Florian R Greten, Gareth J Inman, Owen J Sansom
Recent studies have suggested increased plasticity of differentiated cells within the intestine to act both as intestinal stem cells (ISCs) and tumour-initiating cells. However, little is known of the processes that regulate this plasticity. Our previous work has shown that activating mutations of Kras or the NF-κB pathway can drive dedifferentiation of intestinal cells lacking Apc. To investigate this process further, we profiled both cells undergoing dedifferentiation in vitro and tumours generated from these cells in vivo by gene expression analysis...
June 16, 2017: Cell Death and Differentiation
https://www.readbyqxmd.com/read/28622036/molecular-targeted-drugs-and-treatment-of-colorectal-cancer-recent-progress-and-future-perspectives
#19
Fang Geng, Zheng Wang, Hang Yin, Junxian Yu, Bangwei Cao
Nowadays, colorectal cancer is the fourth most common type of tumor all over the world. When diagnosed, ∼50%-60% of tumors have metastasized, thus resulting in a grim prognosis. Chemotherapy is regarded as standard treatment for patients with colorectal cancer, however, limitations of chemotherapy cannot be ignored, such as low selectivity, insufficient concentrations in tumor tissues, and systemic toxicity. Recently, six targeted drugs have been approved by the U.S. Food and Drug Administration (FDA) for treatment of metastatic colorectal cancer (mCRC), including bevacizumab, aflibercept, regorafenib, cetuximab, and panitumumab...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28621643/the-clinical-effectiveness-of-different-surveillance-strategies-to-prevent-colorectal-cancer-in-people-with-intermediate-grade-colorectal-adenomas-a-retrospective-cohort-analysis-and-psychological-and-economic-evaluations
#20
Wendy Atkin, Amy Brenner, Jessica Martin, Katherine Wooldrage, Urvi Shah, Fiona Lucas, Paul Greliak, Kevin Pack, Ines Kralj-Hans, Ann Thomson, Sajith Perera, Jill Wood, Anne Miles, Jane Wardle, Benjamin Kearns, Paul Tappenden, Jonathan Myles, Andrew Veitch, Stephen W Duffy
BACKGROUND: The UK guideline recommends 3-yearly surveillance for patients with intermediate-risk (IR) adenomas. No study has examined whether or not this group has heterogeneity in surveillance needs. OBJECTIVES: To examine the effect of surveillance on colorectal cancer (CRC) incidence; assess heterogeneity in risk; and identify the optimum frequency of surveillance, the psychological impact of surveillance, and the cost-effectiveness of alternative follow-up strategies...
April 2017: Health Technology Assessment: HTA
keyword
keyword
32505
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"